Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways
Sandra E. Ghayad(Inserm), Pascale A. Cohen(Lyon 1 Université), Charles Dumontet(Centre de Recherche en Cancérologie de Lyon), Ivan Bièche(Centre National de la Recherche Scientifique), Julie A. Vendrell(Inserm), Sabrina Ben Larbi(Lyon 1 Université)
Cited by 131
Related Papers
Antibody–drug conjugates come of age in oncology
|Nature Reviews Drug Discovery|2023|772
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
|The Lancet Oncology|2014|410
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
|Annals of Oncology|2024|343
Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors
|Endocrine Reviews|2011|302